BioAtla and GATC Health announced a SPV transaction to advance ozuriftamab vedotin in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma/ As part of the SPV transaction, BioAtla will receive an initial $5M for general operating and 2L+ OPSCC clinical trial expenses from Inversagen AI, a newly formed company with a mission to cure age-related diseases. Inversagen AI was formed by GATC Health and Inversagen. The initial closing of the SPV transaction will occur concurrently with the initial closing of Inversagen AI'ss financing and is expected to occur by January 30, 2026, with the remaining $35M anticipated to close later in Q1 2026 when the Oz-V registrational clinical study is expected to begin, in each case subject to completion of financings by Inversagen AI and customary closing conditions. Inversagen AI will receive an aggregate 35% ownership stake in Oz-V, while BioAtla will retain 65% ownership across all Oz-V solid tumor indications after completion of the transaction. BioAtla and GATC Health also expect to collaborate with Inversagen AI for the research and development of CAB senolytic therapies with BioAtla maintaining rights to the cancer therapeutic applications of these new therapies.
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.353
Low
10.00
Averages
10.00
High
10.00
Current: 0.353
Low
10.00
Averages
10.00
High
10.00
Citizens JMP
Reni Benjamin
Outperform -> Market Perform
downgrade
$NULL
2025-08-13
Reason
Citizens JMP
Reni Benjamin
Price Target
$NULL
AI Analysis
2025-08-13
downgrade
Outperform -> Market Perform
Reason
Citizens JMP analyst Reni Benjamin downgraded BioAtla to Market Perform from Outperform without a price target following the Q2 report. The firm views the shares as fairly valued given expecatatations for no revenue or earnings in the near future. BioAtla is facing an evolving landscape and uncertainty regarding a potential partnership, the analyst tells investors in a research note. With a partnership, Citizens views the company's current cash position as insufficient to sustain operations.
HC Wainwright & Co.
Arthur He
Hold
Reiterates
n/a
2025-03-31
Reason
HC Wainwright & Co.
Arthur He
Price Target
n/a
2025-03-31
Reiterates
Hold
Reason
Citizens Capital Markets
Reni Benjamin
Buy
Maintains
$5 → $1
2025-03-31
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$5 → $1
2025-03-31
Maintains
Buy
Reason
Citizens JMP analyst Reni Benjamin lowered the firm's price target on BioAtla to $1 from $5 and keeps an Outperform rating on the shares following the Q4 report. With initial data for BA3182 expected in mid-2025, three other assets seeking potential partnership opportunities, and a cash position of $49M, the shares could rebound if we see some "interesting data" with the T cell engaging asset or a potential partner provides non-dilutive capital, the analyst tells investors in a research note. Citizens believes there is an "asymmetric risk setup towards the upside, if any of the ongoing partnership discussions materialize."
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
